Showing 141-150 of 218 results for "".
Menopause and the Skin
https://modernaesthetics.com/ma-issues-index/2024-may-june/menopause-and-the-skin/35369/The impact and potential mitigation of estrogen lossBoard Forum | Hack Your Practice: Save Time and Money
https://modernaesthetics.com/ma-issues-index/2018-may-june/board-forum-hack-your-practice-save-time-and-money/34117/- Xeomin Performs Well in Phase 3 Studies of Upper Facial Lineshttps://modernaesthetics.com/news/xeomin-performs-well-in-phase-3-studies-of-upper-facial-lines/2473428/Two pivotal phase 3 clinical studies demonstrated the efficacy and safety of Xeomin (incobotulinumtoxinA) in the simultaneous treatment of horizontal forehead lines, glabellar frown lines, and lateral canthal lines, according to Merz Aesthetics. Merz Aesthetics will submit these data as
- Evolus Acquires Exclusive US Distribution Rights to Evolysse Line of Dermal Fillershttps://modernaesthetics.com/news/evolus-acquires-exclusive-us-distribution-rights-to-evolysse-line-of-dermal-fillers/2473412/Evolus has entered into a definitive agreement to be the exclusive US distributor of a line of five dermal fillers currently in late-stage development. Evolus is partnering with Symatese, a privately held French company, to introduce the Evolysse line to its US customers beginning
- Top-line Phase 3 Data Promising for Galderma's RelabotulinumtoxinAhttps://modernaesthetics.com/news/top-line-phase-3-data-promising-for-galdermas-relabotulinumtoxina/2473250/Galderma’s investigational RelabotulinumtoxinA, a novel liquid formulation botulinum toxin A, improves both glabellar and lateral canthal lines with a rapid onset of action and a long duration up to six months, according to top-line phase 3 data presen
- Allergan Aesthetics Submits BLA for TrenibotulinumtoxinE for Glabellar Lineshttps://modernaesthetics.com/news/abbvie-submits-bla-for-trenibotulinumtoxine-for-glabellar-lines/2475351/Allergan Aesthetics, an AbbVie Company, has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for trenibotulinumtoxinE (TrenibotE), seeking approval for the treatment of moderate to severe glabellar lines. TrenibotE, a serotype E botulinum toxin
- FDA Approves South Korean Neurotoxin for Frown Lineshttps://modernaesthetics.com/news/fda-approves-south-korean-neurotoxin-for-frown-lines/2473751/The US Food and Drug Administration approved the neurotoxin, Letybo (letibotulinumtoxinA-wlbg), to treat moderate-to-severe glabellar lines in adults, Hugel Inc. announced last week. According to a press release, Hugel Inc. plans to accelerate its transition for approved medical use with
- New Ophthalmologist-Created Eye Skincare Line Launcheshttps://modernaesthetics.com/news/new-ophthalmologist-created-eye-skincare-line-launches/2473236/Now available for pre-order, Daily Practice, the new eye care line by Ashley Brissette, MD, has launched with a hero product—Eye Revive. Having worked as an ophthalmologist for six years, New York City-based Dr. Brissette says she recognized a grow
- First, Only US Neurotoxin for Simultaneous Treatment of Upper Facial Lines Gets FDA Approvalhttps://modernaesthetics.com/news/first-only-us-neurotoxin-for-simultaneous-treatment-of-upper-facial-lines-gets-fda-approval/2473638/Merz Aesthetics announced the US Food and Drug Administration approved XEOMIN (incobotulinumtoxinA) as the first and only neurotoxin for the simultaneous treatment of upper facial lines – forehead lines, frown lines, and crow’s feet. XEOMIN was first approved in 2011 f
- Teoxane Launches Consumer Access to Dermocosmetic Skincare Line in U.S.https://modernaesthetics.com/news/teoxane-launches-consumer-access-to-dermocosmetic-skincare-line-in-us/2475362/Teoxane has announced the U.S. launch of its dermocosmetics line, making its clinically developed skincare products available directly to consumers for the first time through its new online platform, teoxane.us. Previously offered exclusively through aesthetic professionals, the Swiss comp